Drug Guidance for Subsidy 16/09/2025 Sucroferric oxyhydroxide for treating hyperphosphataemia in patients with end-stage renal disease on dialysis The Ministry of Health’s Drug Advisory Committee has recommended: Sucroferric oxyhydroxide 50... See all × 16/09/2025 Sucroferric oxyhydroxide for treating hyperphosphataemia in patients with end-stage renal disease on dialysis The Ministry of Health’s Drug Advisory Committee has recommended: Sucroferric oxyhydroxide 500 mg chewable tablet for treating hyperphosphataemia in patients with end-stage renal disease on haemodialysis or peritoneal dialysis who have persistent hyperphosphataemia despite optimising treatment with calcium-based phosphate binders, or who are unable to tolerate calcium-based phosphate binders due to hypercalcaemia. Funding status RSucroferric oxyhydroxide 500 mg chewable tablet is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 November 2025.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet, Chewable 500 mg National University Hospital Sengkang General Hospital Singapore General Hospital